Delivra Health Brands Inc. (DHB.V)
CAD 0.17
(0.0%)
CAD 0.17
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.35 Million CAD | 7233.33% |
| 2022 | 1.39 Million CAD | 99.15% |
| 2021 | -4.25 Million CAD | 44.73% |
| 2020 | -7.04 Million CAD | 47.24% |
| 2019 | -55.4 Million CAD | 22.9% |
| 2018 | -25.4 Million CAD | -26.06% |
| 2017 | -10.24 Million CAD | -140.09% |
| 2016 | -7.19 Million CAD | -12271.07% |
| 2015 | -46.25 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | 147 Thousand CAD | 191.88% |
| 2023 Q4 | 1.8 Million CAD | 1127.21% |
| 2023 Q2 | -160 Thousand CAD | -126.49% |
| 2023 Q1 | 604 Thousand CAD | 14.83% |
| 2022 Q3 | -296 Thousand CAD | -401.69% |
| 2022 Q4 | 526 Thousand CAD | 277.7% |
| 2022 Q2 | -59 Thousand CAD | 70.79% |
| 2022 FY | - CAD | 99.15% |
| 2022 Q1 | -202 Thousand CAD | 81.21% |
| 2021 Q1 | -927 Thousand CAD | 0.0% |
| 2021 FY | - CAD | 44.73% |
| 2021 Q4 | -1.07 Million CAD | -55.8% |
| 2021 Q3 | -690 Thousand CAD | 42.6% |
| 2021 Q2 | -1.2 Million CAD | -29.67% |
| 2020 FY | - CAD | 47.24% |
| 2019 FY | - CAD | 22.9% |
| 2018 FY | - CAD | -26.06% |
| 2017 FY | - CAD | -140.09% |
| 2016 FY | - CAD | -12271.07% |
| 2015 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | -2.68 Million CAD | 187.791% |
| CanadaBis Capital Inc. | 5.67 Million CAD | 58.541% |
| Decibel Cannabis Company Inc. | 5.67 Million CAD | 58.549% |
| Entourage Health Corp. | -21.39 Million CAD | 111.002% |
| Lifeist Wellness Inc. | -12.76 Million CAD | 118.434% |
| Cannara Biotech Inc. | 17.18 Million CAD | 86.304% |
| Medicure Inc. | 1.27 Million CAD | -84.918% |
| PharmaCielo Ltd. | -12.01 Million CAD | 119.586% |
| Rubicon Organics Inc. | 1.94 Million CAD | -20.842% |
| BioSyent Inc. | 9.05 Million CAD | 74.011% |
| Voyageur Pharmaceuticals Ltd. | -1.22 Million CAD | 292.8% |